Clinical Trial Update: Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial comparing standard-dose imatinib with high-dose induction in pretreated patients with chronic-phase chronic myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Gleevec (Imatinib)

Snippet

Sponsor: Central European Leukemia Study Group | Conditions: Chronic Myeloid Leukemia | Phase 3 | Status: UNKNOWN